5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Therapeutic Applications of Functional Nanomaterials for Prostatitis

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Prostatitis is a common disease in adult males, with characteristics of a poor treatment response and easy recurrence, which seriously affects the patient’s quality of life. The prostate is located deep in the pelvic cavity, and thus a traditional infusion or other treatment methods are unable to easily act directly on the prostate, leading to poor therapeutic effects. Therefore, the development of new diagnostic and treatment strategies has become a research hotspot in the field of prostatitis treatment. In recent years, nanomaterials have been widely used in the diagnosis and treatment of various infectious diseases. Nanotechnology is a promising tool for 1) the accurate diagnosis of diseases; 2) improving the targeting of drug delivery systems; 3) intelligent, controlled drug release; and 4) multimode collaborative treatment, which is expected to be applied in the diagnosis and treatment of prostatitis. Nanotechnology is attracting attention in the diagnosis, prevention and treatment of prostatitis. However, as a new research area, systematic reviews on the application of nanomaterials in the diagnosis and treatment of prostatitis are still lacking. In this mini-review, we will highlight the treatment approaches for and challenges associated with prostatitis and describe the advantages of functional nanoparticles in improving treatment effectiveness and overcoming side effects.

          Related collections

          Most cited references152

          • Record: found
          • Abstract: found
          • Article: not found

          Smart cancer nanomedicine

          Nanomedicines are extensively employed in cancer therapy. We here propose four strategic directions to improve nanomedicine translation and exploitation. (1) Patient stratification has become common practice in oncology drug development. Accordingly, probes and protocols for patient stratification are urgently needed in cancer nanomedicine, to identify individuals suitable for inclusion in clinical trials. (2) Rational drug selection is crucial for clinical and commercial success. Opportunistic choices based on drug availability should be replaced by investments in modular (pro)drug and nanocarrier design. (3) Combination therapies are the mainstay of clinical cancer care. Nanomedicines synergize with pharmacological and physical co-treatments, and should be increasingly integrated in multimodal combination therapy regimens. (4) Immunotherapy is revolutionizing the treatment of cancer. Nanomedicines can modulate the behaviour of myeloid and lymphoid cells, thereby empowering anticancer immunity and immunotherapy efficacy. Alone and especially together, these four directions will fuel and foster the development of successful cancer nanomedicine therapies.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Fundamentals of TiO 2 Photocatalysis: Concepts, Mechanisms, and Challenges

              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Bacterial resistance to silver nanoparticles and how to overcome it

                Bookmark

                Author and article information

                Contributors
                Journal
                Front Pharmacol
                Front Pharmacol
                Front. Pharmacol.
                Frontiers in Pharmacology
                Frontiers Media S.A.
                1663-9812
                28 May 2021
                2021
                : 12
                : 685465
                Affiliations
                [ 1 ]Department of Urology, Guangzhou Institute of Urology, Guangdong Key Laboratory of Urology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
                [ 2 ]The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
                [ 3 ]Department of Interventional Radiology, Cancer Center, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, China
                [ 4 ]State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, China
                [ 5 ]Guangdong Provincial People’s Hospital, School of Medicine, South China University of Technology, Guangzhou, China
                Author notes

                Edited by: Jiang Pi, Guangdong Medical University, China

                Reviewed by: An Guo Wu, Southwest Medical University, China

                Di Liu, Capital Medical University, China

                *Correspondence: Zhi-Jin Fan, fanzhj5@ 123456mail.sysu.edu.cn ; Hong-Xing Liu, liuhongxing@ 123456gzhmu.edu.cn
                [†]

                These authors have contributed equally to this work

                This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology

                Article
                685465
                10.3389/fphar.2021.685465
                8205439
                34140892
                c63a692a-4904-4ac6-b59a-ddd95cc903e7
                Copyright © 2021 Liu, Chen, Ye, He, Dang, Li, Wang, Ren, Fan and Liu.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 25 March 2021
                : 10 May 2021
                Categories
                Pharmacology
                Mini Review

                Pharmacology & Pharmaceutical medicine
                prostatitis,functional nanoparticle,inflammatory microenvironment,engineering strategy,reactive oxygen species

                Comments

                Comment on this article